APA
SMMT icon

American Portfolios Advisors’s Summit Therapeutics SMMT Stock Holding History

American Portfolios Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$3.44K – 3091
2020
Q3 		$3.44K Hold
1,000
– – ﹤0.01% 2422
2020
Q2 		$2.97K Buy
+1,000
New +$3.45K ﹤0.01% 2415

Other funds holding SMMT

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

American Portfolios Advisors's SMMT Position: Q4 2020 in Review

American Portfolios Advisors sold out of Summit Therapeutics (SMMT) in Q4 2020, closing a stake of 1,000 shares — an estimated $3.44K sold.

American Portfolios Advisors first reported a position in SMMT in Q2 2020 and held it in 2 quarters. The position peaked at $3.44K in Q3 2020. 37 funds tracked by Wall St. Rank hold SMMT as of Q4 2020.

  • American Portfolios Advisors reported no remaining Summit Therapeutics position as of Q4 2020 after selling out during the quarter.
  • American Portfolios Advisors sold 1,000 Summit Therapeutics shares in Q4 2020, an estimated $3.44K.
  • American Portfolios Advisors first reported a position in Summit Therapeutics in Q2 2020 and held it in 2 quarters.
  • American Portfolios Advisors's Summit Therapeutics position peaked at $3.44K in Q3 2020.
  • 37 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2020.

Based on American Portfolios Advisors's 13F filing for Q4 2020, filed 22 Mar 2023.